grant
Investigating mechanisms of bladder cancer metastasis
Organization COLUMBIA UNIVERSITY HEALTH SCIENCESLocation NEW YORK, UNITED STATESPosted 19 Sept 2023Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY2025ARID1AARID1A geneAT- rich interactive domain-containing protein 1AAT-rich interactive domain 1A geneAlgorithmsAntioncogene Protein p53AssayBioassayBiological AssayBiological FunctionBiological ProcessBiologyBladderBladder CancerBladder Urinary SystemCancer CauseCancer Causing AgentsCancer EtiologyCancer PatientCancersCarcinogensCell BodyCellsCellular Tumor Antigen P53Cessation of lifeComputational algorithmDataDeathDiseaseDisease OutcomeDisorderDoseDrug TargetingDrugsEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEvolutionFoundationsGEM modelGEMM modelGenetically Engineered MouseGoalsHealthHumanIncidenceInvestigationLineage TracingMalignant Bladder NeoplasmMalignant NeoplasmsMalignant TumorMalignant Tumor of the BladderMalignant neoplasm of urinary bladderMedicationMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMetastatic toMiceMice MammalsModelingModern ManMolecularMolecular AnalysisMurineMusNeoplasm MetastasisNitrosaminesOncogenesisOncogensOncoprotein p53OrganOrganoidsOutcomeP53Pathway interactionsPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPharmaceutical PreparationsPhosphoprotein P53Phosphoprotein pp53Protein TP53ReporterResearchSecondary NeoplasmSecondary TumorSiteSystemSystems BiologyTP53TP53 geneTRP53Tumor Protein p53Tumor Protein p53 GeneUnited StatesUrinary Bladder CancerUrinary Bladder Malignant Tumoractionable mutationactionable variantsanalyzing longitudinalbiobankbiorepositorycancer metastasiscancer microenvironmentcandidate identificationcell lineage analysiscell lineage mappingcell lineage tracingcell lineage trackingcellular lineage mappingcellular lineage trackingcomputer algorithmdriver lesiondriver mutationdrug candidatedrug/agentepigeneticallygenetically engineered mouse modelgenetically engineered murine modelimprovedin vitro Modelin vivoin vivo Modellongitudinal analysisloss of functionmalignancymuscle invasive bladder cancerneoplasm/cancernew approachesnew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic targetnew therapeuticsnew therapynew therapy targetnext generation therapeuticsnon-muscle invasive bladder cancernovelnovel approachesnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel strategiesnovel strategynovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetoncogenic agentp53 Antigenp53 Genesp53 Tumor Suppressorpathwaypatient oriented outcomespre-clinicalpreclinicalprotein p53scRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingtranslational goaltranslational missiontumortumor cell metastasistumor microenvironmenttumorigenesisurinary bladder
Description preview
The major cause of bladder cancer deaths is due to metastasis, yet to date metastatic bladder cancer
(mMIBC) has not been extensively studied and many salient issues remain unresolved. One of the major
challenges that has hampered progress in studying mMIBC is the lack of suitable models to investigate
metastatic progression in vivo. We have now…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click